Ethmozine®(moricizine hydrochloride) Tablets
Ethmozine® (moricizine hydrochloride) is an orally active antiarrhythmic drug available for administration in tablets containing 200 mg, 250 mg and 300 mg of moricizine hydrochloride.
Ethmozine® is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician are life-threatening. Because of the proarrhythmic effects of Ethmozine®, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided.
Initiation of Ethmozine® treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias.
Published Studies Related to Ethmozine (Moricizine)
Effect of moricizine on heart rate variability in normal subjects. [1995.01.27]
We investigated the effects of moricizine HCl, a type Ic anti-arrhythmic agent, on heart rate variability... This decrease produced by moricizine is similar to that reported with other type 1 antiarrhythmics.
Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). [1994.12]
CONCLUSIONS: Although active treatment in CAST-I was associated with greater mortality than placebo with respect to almost all baseline variables, the therapeutic hazard was more than expected in patients with non-Q-wave myocardial infarction and (for total mortality) frequent premature VPDs and higher heart rates, suggesting that the adverse effect of encainide or flecainide therapy is greater when ischemic and electrical instability are present. The relative hazard of therapy with moricizine in the sicker CAST-II population was greater in those using diuretics. Thus, although these drugs have the common ability to suppress ventricular ectopy after myocardial infarction, their detrimental effects on survival may be mediated by different mechanisms in different populations, emphasizing the complex, poorly understood hazards associated with antiarrhythmic drug treatment.
Moricizine and quality of life in the Cardiac Arrhythmia Suppression Trial II (CAST II). [1994.12]
The Cardiac Arrhythmia Suppression Trial II (CAST II) was a double-masked placebo-controlled randomized trial that compared the survival effects of moricizine to placebo in postmyocardial infarction arrhythmia patients. The quality-of-life outcome measures were designed prospectively for CAST and were previously shown to have high reliability and clinical discriminative validity...
Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST). [1994.02]
OBJECTIVES. The purpose of this study was to assess the effect of antiarrhythmic drugs on the timing of arrhythmic death.Planning of future antiarrhythmic drug trials will need to take this information into account.
Enzyme induction by moricizine: time course and extent in healthy subjects. [1994.02]
Moricizine.HCl, a novel phenothiazine derivative with oral antiarrhythmic activity, was examined for its potential to induce its own hepatic metabolism and to alter the pharmacokinetics of the test substrate, antipyrine, in 12 healthy male subjects. Antipyrine oral clearance increased from a starting value of .74 mL/minute/kg to .98 (+32%, P < .01) after 7 days of moricizine administration (250 mg every 8 hours) and to 1.15 mL/minute/kg after 14 days (+47%, P < .05); t1/2 was correspondingly reduced...
Clinical Trials Related to Ethmozine (Moricizine)
Cardiac Arrhythmia Pilot Study (CAPS) [Completed]
Cardiac Arrhythmia Suppression Trial (CAST) [Completed]
To determine whether drug treatment of asymptomatic ventricular arrhythmias in
post-myocardial infarction patients reduced the incidence of sudden cardiac death and total
Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) [Completed]
To compare two standard treatment strategies for atrial fibrillation: ventricular rate
control and anticoagulation vs. rhythm control and anticoagulation.
Page last updated: 2007-06-01